Announcement • May 20
BitFrontier Capital Holdings, Inc. (OTCPK:BFCH) completed the acquisition of VerdaGenix, LLC. BitFrontier Capital Holdings, Inc. (OTCPK:BFCH) entered into a binding letter of intent to acquire VerdaGenix, LLC for $0.49 million on April 21, 2026. The total consideration for the transaction shall be $0.49 million, consisting of equity in BFCH, including the conversion of approximately $0.225 million of existing third-party debt of the Company into equity securities of BFCH. Upon closing, VerdaGenix will operate as a wholly owned subsidiary of the BitFrontier Capital Holdings, Inc.
John P. Gorst will join UNLOCKD’s executive management team.
The transaction is subject to completion of due diligence, execution of definitive agreements, and satisfaction of customary closing conditions.
BitFrontier Capital Holdings, Inc. (OTCPK:BFCH) completed the acquisition of VerdaGenix, LLC on May 20, 2026. Announcement • Feb 18
BitFrontier Capital Holdings, Inc. announced that it has received $0.173259 million in funding BitFrontier Capital Holdings, Inc. announced a private placement of common shares of 216,573,750 at the price of $0.0008 for the gross proceeds of $173,259 on February 17, 2026. Announcement • Aug 05
BitFrontier Capital Holdings, Inc. (OTCPK:BFCH) signed a binding letter of intent to acquire ERApeutics LLC. BitFrontier Capital Holdings, Inc. (OTCPK:BFCH) signed a binding letter of intent to acquire ERApeutics LLC for $0.52 million on August 4, 2025. The consideration consists of 400 million restricted common shares of BitFrontier Capital Holdings, Inc. to be issued for common equity of ERApeutics LLC. Upon completion, EVERMIND™ will operate as a wholly owned subsidiary of EVERMIND Labs, with future spin-off optionality. The transaction is expected to close within 60 to 90 days, subject to standard confirmatory due diligence and final documentation. The acquisition is expected to materially strengthen BFCH’s balance sheet by adding structured, IP-backed assets and aligning with the Company’s OTCQB uplisting strategy. 
